Pharmacy · Independent exam preparation
Pharmacy Technician Certification Examination (PTCE) Study Guide
An independent, blueprint-aligned guide for the PTCB CPhT pathway, with 60 concepts, 20 original practice questions, and 20 flashcards for the January 2026 PTCE outline.
By CertMedbry · Updated 13 October 2026
This guide follows PTCE Content Outline v1.4, dated August 2024 and effective January 6, 2026. The official PTCE Content Outline defines the full scope of the examination; this 60-concept guide is a selective study aid, not a comprehensive review. Review every area in the official outline. The outline assigns 35% to Medications, 18.75% to Federal Requirements, 23.75% to Patient Safety and Quality Assurance, and 22.50% to Order Entry and Processing. The study materials are independently authored; they are not PTCB questions or a prediction of exam performance. Product examples reflect cited labeling and do not replace current labeling, pharmacist direction, applicable law, or workplace procedures.
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
Which credential and examination does this guide cover?
It covers the PTCB Certified Pharmacy Technician (CPhT) credential pathway and its associated Pharmacy Technician Certification Examination (PTCE). CPhT names the credential; PTCE names the examination.
How many PTCE items are scored?
The PTCE has 90 multiple-choice items: 80 scored and 10 unscored. These practice questions are independent study materials, not an exam replica. The exam is computer-based and administered in person at Pearson centers; the two-hour appointment includes a 110-minute exam.
Which blueprint and effective date does this guide use?
It uses PTCE Content Outline v1.4, dated August 2024 and effective January 6, 2026. Its four weights are Medications 35%, Federal Requirements 18.75%, Patient Safety and Quality Assurance 23.75%, and Order Entry and Processing 22.50%. A PTCB FAQ lists 22.25% for the last domain; this guide follows the current outline PDF.
PTCE Content Outline, effective January 6, 2026 · PTCB: At-a-Glance: CPhT Exam
What changed in the January 2026 PTCE scope?
The January 2026 revision removed nonsterile-compounding content and alligation, removed a standalone NTI area, and added DSCSA knowledge. Removal of a standalone area does not mean related safety concepts are absent from every other area.
PTCB: PTCE Job Analysis Study · PTCE Content Outline, effective January 6, 2026
How should a technician approach a REMS flag?
REMS requirements are program-specific. If a system flags a REMS condition that is not documented, do not bypass the flag. Follow that program's current instructions and authorized workflow, and refer eligibility questions or uncertainty to the pharmacist. This guide teaches recognition and escalation only; it does not claim to describe a particular REMS program.
What should I remember about controlled-substance schedules and prescription workflows?
The outline covers DEA schedules and new, refill, and transfer prescriptions. Identify the schedule and transaction type, then use the authorized workflow. A transfer does not make a federally prohibited Schedule II refill permissible. State rules may be stricter; refer uncertain legal or validity questions to the pharmacist.
PTCE Content Outline, effective January 6, 2026 · 21 CFR 1306.12: Refilling prescriptions; issuance of multiple prescriptions · 21 CFR 1306.22: Refilling of prescriptions
What should I know about federal pharmaceutical-waste handling and disposal?
The outline includes federal requirements for storage, handling, and disposal of non-hazardous, hazardous—including P-listed—and pharmacological substances and wastes. Identify that waste handling is a regulated topic, use the applicable current requirements and workplace procedure to determine the correct stream, and ask the pharmacist or designated waste lead when uncertain. This guide does not prescribe a universal disposal route.
Do the federal-law examples apply identically in every U.S. jurisdiction?
No. State and local requirements may be stricter or add obligations. Follow applicable law and workplace procedure, and refer uncertainty to the pharmacist. This guide is not a complete jurisdiction-specific practice manual.
PTCE Content Outline, effective January 6, 2026 · 21 CFR 1306.12: Refilling prescriptions; issuance of multiple prescriptions · 21 CFR 1306.22: Refilling of prescriptions
CPhT is the PTCB credential; PTCE is its associated examination. Federal examples describe U.S. federal requirements, and state or local rules may be stricter. The January 2026 outline removed nonsterile compounding and alligation and removed a standalone narrow-therapeutic-index area; related issues may still arise elsewhere. This guide follows the current outline PDF for weights: Order Entry and Processing is 22.50%; a PTCB FAQ lists 22.25%, a discrepancy this guide does not resolve by substituting the FAQ figure. The 20 flashcards use a 7/4/5/4 domain distribution; the 20-question sample instead contains 6 Medications, 5 Federal Requirements, 5 Patient Safety and Quality Assurance, and 4 Order Entry and Processing questions.
Outline used: PTCE Content Outline v1.4, dated August 2024, effective January 6, 2026; verified against live issuer sources on October 9, 2026. The workbook label 'Pharmacy - Certified Pharmacy Technician (PTCB CPhT)' identifies the CPhT credential; its associated examination is the PTCE. The assigned canonical slug is preserved.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
Medications35%
1.How do brand and generic names help identify a medication?
A generic name identifies the active ingredient, while a brand name identifies a marketed product. DailyMed identifies Lipitor as atorvastatin, a statin. Confirm strength, dosage form, and release characteristics; shared ingredients alone do not establish identical products or automatic interchangeability. Refer substitution questions through authorized workflow to the pharmacist. This is brand-to-generic identification, not a substitution decision.
Apply it
If asked whether Lipitor and atorvastatin refer to the same active drug, recognize the relationship and confirm the ordered strength and form against the selected product.
Common pitfall: Do not assume matching ingredients mean matching strengths, dosage forms, or release characteristics. Refer substitution questions to the pharmacist.
PTCE Content Outline, effective January 6, 2026 · DailyMed: LIPITOR — atorvastatin calcium
2.What clue suggests a possible therapeutic duplication?
Overlapping therapies may involve the same ingredient under different names or two medicines from a similar class. An alert is a reason to verify, not proof of an error; intentional combinations and transitions can create apparent overlap. Compare ingredients and directions, then refer unexplained overlap to the pharmacist for clinical review. A technician identifies and escalates rather than canceling therapy independently.
Apply it
Two active prescriptions appear to list atorvastatin under different labels. Compare the ingredients and directions, then route unresolved overlap to the pharmacist.
Common pitfall: Do not cancel an order independently or reassure the patient merely because product names differ. The pharmacist assesses clinical intent.
PTCE Content Outline, effective January 6, 2026 · DailyMed: LIPITOR — atorvastatin calcium
3.Why does an NSAID matter when a patient uses warfarin?
Warfarin labeling warns that NSAIDs can increase bleeding risk. Recognize the potential interaction and bring it to the pharmacist; labeling supports recognition, not an individual treatment decision. OTC status does not eliminate interaction risk or the need for review. The pharmacist assesses patient-specific use and risk; the technician does not recommend a product or dose change before that review. Refer before the patient proceeds.
Apply it
A patient taking warfarin asks about adding an OTC NSAID. Refer the question to the pharmacist before the patient proceeds; do not recommend a product.
Common pitfall: Do not treat OTC status or short-term use as proof of safety, or recommend a dose change. Leave individual assessment to the pharmacist.
PTCE Content Outline, effective January 6, 2026 · DailyMed: Warfarin sodium tablets
4.Which combination is a major nitroglycerin safety concern?
Nitroglycerin labeling contraindicates concomitant use with phosphodiesterase-5 (PDE-5) inhibitors because the combination can cause a dangerous decrease in blood pressure. Promptly refer the concern to the pharmacist. Recognizing and escalating the combination is the task; the technician does not calculate a safe interval or change either medicine. The pharmacist assesses the patient's circumstances and next steps. Do not independently alter either medicine.
Apply it
A patient mentions PDE-5 inhibitor use while asking about nitroglycerin. Pause routine handoff and obtain pharmacist review promptly; do not suggest a timing interval.
Common pitfall: Do not assume different administration times make the combination safe or invent a washout interval. Refer patient-specific assessment to the pharmacist.
PTCE Content Outline, effective January 6, 2026 · DailyMed: NITROSTAT — nitroglycerin tablets
5.How can dietary vitamin K affect a warfarin medication history?
Warfarin labeling emphasizes consistency in dietary vitamin K intake. A substantial diet or supplement change may matter to anticoagulation management. Capture the concern accurately and refer it to the pharmacist; do not adjust doses or prescribe a diet. This is a drug-nutrient interaction recognition task, not a diet plan. Never tell a patient to eliminate every food containing vitamin K based on this teaching point.
Apply it
A patient taking warfarin reports a substantial change in leafy-green intake while starting a diet. Record the concern and refer it to the pharmacist.
Common pitfall: Do not advise avoiding all vitamin K-containing foods or changing the prescribed dose. Patient-specific advice belongs with the pharmacist and appropriate prescriber.
PTCE Content Outline, effective January 6, 2026 · DailyMed: Warfarin sodium tablets
6.Why must extended-release metformin tablets be handled as directed?
The metformin ER product labeling instructs patients to swallow the tablet whole rather than crush, cut, or chew it. Altering a modified-release form can change delivery. Refer swallowing difficulty or requests to alter the dosage form to the pharmacist. Compare the exact release formulation with the order; an immediate-release product has different characteristics. The label instruction is product-specific.
Apply it
A patient asks whether a metformin ER tablet can be crushed. Pause and refer the question to the pharmacist for review against the exact product label.
Common pitfall: Do not apply directions for an immediate-release product to an extended-release product with the same ingredient. Ingredient similarity does not erase formulation differences.
PTCE Content Outline, effective January 6, 2026 · DailyMed: Metformin hydrochloride extended-release tablets
7.When should a technician recognize a levothyroxine timing concern?
Levothyroxine labeling describes administration on an empty stomach and separation from products such as calcium carbonate or iron because they can interfere with absorption. Refer patient-specific timing questions to the pharmacist. Use the exact product information without creating a schedule that conflicts with patient-specific directions. The label supports recognition of a potential interaction or administration issue; it is not individualized advice.
Apply it
A patient reports taking levothyroxine with calcium at breakfast. Refer the timing question to the pharmacist and accurately relay the products involved.
Common pitfall: Do not assume oral medicines and supplements cannot interact or devise an individualized schedule without pharmacist direction.
PTCE Content Outline, effective January 6, 2026 · DailyMed: Levothyroxine sodium tablets
8.How does a reconstituted oral suspension differ from a ready-to-use liquid?
A powder for oral suspension must be prepared according to its product directions; a ready-to-use liquid does not require that step. Preparation can affect storage and discard instructions. The amoxicillin suspension labeling gives a product-specific 14-day discard instruction. Check the exact product information and pharmacy directions. The discard period is not a universal rule for all suspensions. Verify preparation, storage, and discard details for the exact product.
Apply it
After the amoxicillin suspension is reconstituted, ensure its product-specific storage and discard directions are communicated with the dispensed product.
Common pitfall: Do not apply the 14-day instruction to every oral suspension. Stability and discard periods depend on the product and labeling.
PTCE Content Outline, effective January 6, 2026 · DailyMed: Amoxicillin for oral suspension
9.Which route is associated with an albuterol HFA inhaler?
An albuterol HFA aerosol is administered by inhalation, and its labeling identifies its use for bronchospasm. Route recognition matters because device and directions depend on dosage form. If the selected item does not match the ordered route or form, stop and resolve the mismatch through authorized workflow. Refer technique questions to the pharmacist. An oral product is not interchangeable merely because its ingredient name is similar.
Apply it
An order requests an albuterol HFA inhaler, but the selected item is an oral product. Compare route and dosage form, then resolve the mismatch through authorized workflow.
Common pitfall: Do not let ingredient recognition obscure a route mismatch. Questions about patient-specific use or technique should go to the pharmacist.
PTCE Content Outline, effective January 6, 2026 · DailyMed: Albuterol sulfate HFA inhalation aerosol
10.What general indication is associated with albuterol?
Albuterol HFA labeling identifies the medicine as a bronchodilator used for bronchospasm. Connect the medicine with its general labeled use, but do not infer an individual diagnosis or judge treatment appropriateness from the prescription alone. Refer patient-specific symptoms and treatment questions to the pharmacist. General indication knowledge is not a diagnosis or individualized recommendation; use current product labeling for product facts.
Apply it
A patient asks why an albuterol inhaler was prescribed. State its general labeled role and refer questions about their symptoms or treatment to the pharmacist.
Common pitfall: Do not conclude that the inhaler is appropriate for every breathing complaint. A general indication is not an individual diagnosis.
PTCE Content Outline, effective January 6, 2026 · DailyMed: Albuterol sulfate HFA inhalation aerosol
11.Which reported effects should prompt pharmacist referral for albuterol?
Albuterol labeling lists possible effects such as tremor, nervousness, and palpitations. Listen, record the concern according to procedure, and involve the pharmacist, especially when a report sounds severe or urgent. The technician recognizes and relays; the pharmacist assesses severity and follow-up. A listed effect should not be dismissed without review; labeling alone does not establish a particular patient's cause or severity.
Apply it
A patient reports new palpitations after using albuterol. Promptly bring the report to the pharmacist and follow workplace procedures rather than reassuring the patient.
Common pitfall: Do not diagnose an adverse reaction or tell the patient the symptom is harmless because it appears in labeling. The pharmacist assesses the report.
PTCE Content Outline, effective January 6, 2026 · DailyMed: Albuterol sulfate HFA inhalation aerosol
12.How should a reported penicillin allergy affect amoxicillin processing?
Amoxicillin is a penicillin-class antibiotic, and its labeling warns about hypersensitivity reactions. A documented allergy or newly reported previous reaction merits pharmacist attention before routine processing continues. Capture the report accurately; the technician does not determine whether the reaction was a true allergy or whether a related medicine is safe for that person. Preserve the patient's words and follow the pharmacy's escalation process.
Apply it
A patient collecting amoxicillin reports a previous penicillin reaction absent from the profile. Pause routine completion and alert the pharmacist before proceeding.
Common pitfall: Do not delete an allergy entry, reinterpret the reaction, or assume it was mild without pharmacist review.
PTCE Content Outline, effective January 6, 2026 · DailyMed: Amoxicillin for oral suspension
13.Why are stability instructions product-specific?
Stability can depend on the exact drug, dosage form, packaging, preparation, and storage. A powder and its reconstituted suspension need not have the same stability period. The outline names suspensions, insulins, reconstitutables, injectables, and vaccinations as examples, not universal discard rules. Use exact product labeling and pharmacy instructions; refer missing or conflicting information to the pharmacist. Product-specific instructions should not be generalized across a drug class.
Apply it
Two prepared suspensions have different discard periods. Check the product selected for the current order rather than copying another product's date or directions.
Common pitfall: Do not turn a familiar beyond-use period into a class-wide rule. Use current, product-specific information and ask the pharmacist when uncertain.
PTCE Content Outline, effective January 6, 2026 · DailyMed: Amoxicillin for oral suspension
14.How should nitroglycerin tablets be stored according to the product label?
Nitrostat labeling instructs that sublingual tablets remain in their original glass container, tightly capped. Packaging is part of the product-specific storage instruction. Refer questions about tablets transferred or stored incorrectly to the pharmacist. Do not generalize the instruction to every tablet. Check exact product labeling and pharmacy procedure before changing packaging or storage conditions.
Apply it
A patient asks whether Nitrostat tablets can be moved into a weekly organizer. Refer the question to the pharmacist and check the original-container instruction.
Common pitfall: Do not assume all tablets may be transferred to organizers without checking packaging and stability requirements for that product.
PTCE Content Outline, effective January 6, 2026 · DailyMed: NITROSTAT — nitroglycerin tablets
54.What is a drug-disease interaction concern?
A drug-disease interaction occurs when a medicine may be unsuitable or risky in the presence of a condition. The outline includes drug-disease interactions among interaction and contraindication topics. Notice relevant alerts or reports and route them for pharmacist assessment; do not diagnose or decide whether therapy is appropriate. The exact product, patient history, and clinical context matter. Preserve information accurately.
Apply it
An order triggers a system warning related to a condition in the profile. Preserve the information and refer the alert to the pharmacist before routine completion.
Common pitfall: Do not dismiss an alert because the patient used the medicine before, or independently approve or reject treatment.
55.How should an incomplete medication history be handled?
An incomplete history can hide duplication, interactions, allergies, or administration concerns. Record available information accurately and follow the pharmacy's process for gathering missing details. If a gap affects a safety question, refer it to the pharmacist rather than assuming the profile is complete. OTC products, supplements, and recent changes may be relevant. Absence from a profile does not prove nonuse. Do not make clinical decisions from incomplete information.
Apply it
A patient mentions a supplement absent from the profile while discussing a new prescription. Record the information and alert the pharmacist if it may affect review.
Common pitfall: Do not treat absence from the profile as proof that a medicine or supplement is not used. Refer clinical questions to the pharmacist.
56.How should a reported adverse effect be escalated?
A suspected adverse effect is a reason to involve the pharmacist, not for a technician to diagnose causation. Escalation is important when symptoms sound severe, worsen, or may involve an interaction. Record the patient's words and follow local procedure. The pharmacist determines clinical response and whether further reporting or follow-up is appropriate. Do not tell the patient to stop or continue based on your own judgment.
Apply it
A patient reports a new symptom after starting a medicine and asks whether to stop it. Capture the concern and promptly connect the patient with the pharmacist.
Common pitfall: Do not direct a patient to discontinue or continue a medicine based on your own assessment of causality or severity.
PTCE Content Outline, effective January 6, 2026 · FDA: Medical Product Safety Information
57.How can medication-class knowledge support safe order processing?
Class recognition helps identify a broad therapeutic or pharmacologic grouping but does not establish interchangeability. Levothyroxine is thyroid hormone replacement. Confirm ingredient, strength, and formulation in the order; route clinical or substitution questions to the pharmacist. The outline includes medication names and classifications. Class recognition is not a diagnosis or authorization to substitute; use exact product information for processing.
Apply it
A list includes levothyroxine and calcium. Recognize the medicine category and refer any patient-specific timing concern to the pharmacist using the exact product and directions.
Common pitfall: Do not infer a patient's diagnosis or decide that a product can be substituted based only on class recognition.
PTCE Content Outline, effective January 6, 2026 · DailyMed: Levothyroxine sodium tablets
58.Why should storage conditions be checked against the exact product?
Storage conditions can differ by product and may involve temperature, light, moisture, or restricted access. Use manufacturer's information and pharmacy policy for the exact item. If stock may have experienced unsuitable conditions, isolate it as directed and obtain pharmacist or designated-person assessment. The outline includes storage examples; it does not replace labeling or establish universal conditions. Do not decide usability from appearance alone.
Apply it
A shipment's indicator suggests a temperature excursion. Keep affected product from routine stock and alert the pharmacist for product-specific assessment.
Common pitfall: Do not assume intact packaging or unchanged appearance proves stability. Do not decide usability without authorized review.
59.How should a technician respond when a medication duration seems unusual?
Duration is part of prescribed therapy, but a technician should not change treatment length based on a general expectation. Compare directions with entered directions and quantity calculations. Bring discrepancies or unusual directions to the pharmacist. The actual prescription and patient context determine the appropriate response. Duration appears in the outline's medication knowledge topics. Do not infer a regimen from common practice.
Apply it
Directions imply a duration that does not match the entered quantity. Recheck arithmetic and report the mismatch for pharmacist review before completing the fill.
Common pitfall: Do not alter quantity or course length merely because it differs from a familiar example. Clarify the actual order.
60.How should a technician handle a potential interaction involving a supplement?
The outline includes drug-supplement interactions. Record the supplement name, product details, and reported use as accurately as possible, then refer interaction or treatment questions to the pharmacist. A supplement's nonprescription status does not establish that it is risk-free or compatible with a prescribed medicine. Use the pharmacist for patient-specific assessment rather than offering reassurance or a dose change.
Apply it
A patient mentions starting an herbal product while filling a prescription. Record the information and refer the potential interaction question to the pharmacist.
Common pitfall: Do not assume a supplement is harmless because it is sold without a prescription. Do not recommend stopping or continuing it independently.
Federal Requirements18.75%
15.How should a technician respond to a REMS processing flag?
REMS requirements are specific to a medication and program. If a system flag indicates that a condition must be verified, pause processing, use the current program instructions and authorized workflow, and refer eligibility questions or uncertainty to the pharmacist. The outline identifies REMS as a restricted-program topic but does not establish the steps of any particular program. This teaching is limited to recognition and escalation.
Apply it
A system flags a REMS condition that is not documented. Do not bypass the flag; follow the program's current instructions and refer uncertainty to the pharmacist.
Common pitfall: Do not assume one REMS workflow applies to every medicine or make clinical eligibility decisions as a technician.
16.How should a technician approach controlled-substance schedules and new or transferred prescriptions?
The outline covers DEA controlled-substance schedules and requirements for new, refill, and transfer prescriptions. First identify the schedule and what type of prescription transaction is requested; then use the applicable authorized workflow and involve the pharmacist for uncertain legal or validity questions. Transfer status does not convert a prohibited Schedule II refill into a permitted refill. Federal and state requirements may differ; this is not a complete transfer rulebook.
Apply it
A request arrives as a transfer, but the prior Schedule II prescription appears to have no remaining lawful refill. Do not enter it as a refill because it was transferred; refer to the pharmacist.
Common pitfall: Do not treat new, refill, and transfer as interchangeable transaction labels or imply a transfer makes a prohibited refill permissible.
PTCE Content Outline, effective January 6, 2026 · 21 CFR 1306.12: Refilling prescriptions; issuance of multiple prescriptions · 21 CFR 1306.22: Refilling of prescriptions
18.Which federal refill limits apply to Schedule III and IV prescriptions?
Under the cited federal regulation, a Schedule III or IV prescription may not be refilled more than five times or more than six months after issuance, whichever limit is reached first. Both count and elapsed time matter. Refer uncertain cases to the pharmacist and check applicable state requirements. These limits do not apply as the Schedule II refill rule; identify the schedule before processing. Do not rely on refill count alone.
Apply it
A Schedule IV prescription already has five refills. Do not enter another federal refill; refer the request to the pharmacist for review of next steps.
Common pitfall: Do not remember only the refill count and overlook the separate six-month limit. State requirements may be stricter.
PTCE Content Outline, effective January 6, 2026 · 21 CFR 1306.22: Refilling of prescriptions
19.How should a controlled-substance inventory discrepancy be handled?
Controlled-substance processes include receiving, storage, ordering, dispensing, returns, loss or theft, and destruction. A discrepancy is a security and documentation concern, not something to silently correct. Preserve relevant records, follow written escalation and reconciliation procedures, and promptly alert the pharmacist or designated responsible person. The outline identifies the topic but does not replace applicable rules or facility policy. Do not invent reporting deadlines or alter records to make counts agree.
Apply it
A controlled-substance count does not match the record at shift change. Secure stock, preserve count information, and notify the responsible pharmacist promptly.
Common pitfall: Do not alter a count, backdate a record, or ignore a discrepancy because it appears small. Use the authorized process.
20.What federal pseudoephedrine limits are relevant to restricted sales?
The cited DEA CMEA information sets federal pseudoephedrine sales limits measured as base: no more than 3.6 grams per purchaser per day and 9 grams in a 30-day period, with separate mail-order limits. The base amount and purchase history matter, not only package tablet count. Follow applicable identity, logbook, and system procedures; state limits may be stricter. These are federal maximums, not an entitlement to purchase.
Apply it
The required system indicates that a requested package would exceed the remaining federal daily base limit. Follow restricted-sale procedure and consult the pharmacist if needed.
Common pitfall: Do not ignore purchase records, separate limits, or stricter state requirements merely because a sale is within one federal limit.
PTCE Content Outline, effective January 6, 2026 · DEA Diversion Control Division: CMEA General Information
21.What administrative step can arise in a pseudoephedrine restricted sale?
The federal CMEA process for retail pseudoephedrine includes purchaser identity-verification and logbook requirements, along with quantity limits. Complete authorized administrative checks and records. If a condition is unmet or uncertain, pause and refer it to the pharmacist. This is a pseudoephedrine-specific example, not a universal REMS workflow or a complete jurisdiction-specific procedure. Follow current requirements and applicable state rules.
Apply it
A required purchaser record is missing during a pseudoephedrine transaction. Do not override the restriction; follow the required workflow and escalate uncertainty.
Common pitfall: Do not assume one restricted program's steps apply to every drug or REMS. Do not make clinical eligibility decisions.
PTCE Content Outline, effective January 6, 2026 · DEA Diversion Control Division: CMEA General Information
22.How do FDA recall classes distinguish levels of risk?
Class I involves a reasonable probability of serious adverse health consequences or death; Class II involves temporary or medically reversible consequences, or a remote probability of serious harm; Class III is not likely to cause adverse health consequences. Class informs urgency but does not replace product and lot details. Follow recall procedure and involve the pharmacist in disposition and patient-impact decisions. Read the complete notice rather than acting on the drug name alone.
Apply it
A notice identifies one affected lot. Compare it with product and lot information in stock, isolate matching units, and escalate according to procedure.
Common pitfall: Do not remove every package of a medicine based only on its name when the notice applies to specified lots. Check the full notice.
PTCE Content Outline, effective January 6, 2026 · FDA: Understanding Drug Recalls
23.What should happen when a prescription product is suspected to be illegitimate?
Under DSCSA procedures, a suspect product should be investigated and quarantined rather than returned to saleable stock while the concern is unresolved. If determined illegitimate, federal notification obligations include notifying FDA and specified trading partners within 24 hours of that determination. Preserve product and transaction information and alert the responsible person. A suspicious package is not automatically confirmed illegitimate. Follow the applicable DSCSA process.
Apply it
A package has suspicious serialization information. Segregate it from usable inventory, preserve identifying records, and notify the responsible pharmacist for investigation.
Common pitfall: Do not dispense a suspect product during investigation or report it as confirmed illegitimate before the required determination.
PTCE Content Outline, effective January 6, 2026 · FDA: Pharmacists — Utilize DSCSA Requirements to Protect Your Patients · FDA: Notify FDA of Illegitimate Products
24.How do controlled-substance take-back and reverse-distribution processes differ?
Take-back programs and reverse distribution are distinct ways of handling medicines no longer intended for dispensing. Controlled-substance rules govern receiving, return, transfer, and destruction, so ordinary stock-return workflows may not apply. Follow the authorized program and documented custody steps; ask the pharmacist when status or destination is uncertain. Specific operating requirements depend on the program and applicable regulations. Do not treat a returned controlled medicine as ordinary inventory.
Apply it
A patient brings back an unused controlled medicine. Do not place it into dispensable inventory; direct it to the pharmacy's authorized take-back process.
Common pitfall: Do not assume every return route is authorized for controlled substances or that patient-returned medication can be restocked.
25.Why must controlled substances be secured and documented?
Secure storage and reliable records support accountability from receipt through dispensing, return, loss, or destruction. A locked location alone does not replace documentation. Follow authorized access controls and facility recordkeeping. Federal and state details can differ, so use current law and policy rather than inventing procedures from a general study example. Records help investigate discrepancies and trace handling.
Apply it
A controlled-medication delivery arrives. Verify it through the required receiving procedure, secure it promptly, and ensure authorized staff record the transaction.
Common pitfall: Do not leave controlled stock unattended merely because delivery paperwork is signed. Follow access and documentation controls throughout handling.
53.What should a technician do when pharmaceutical waste needs handling or disposal?
The outline covers federal requirements for storage, handling, and disposal of non-hazardous, hazardous—including P-listed—and pharmacological substances and wastes. First recognize the material and waste stream as a regulated handling issue. Use current applicable federal requirements and the workplace's designated procedure to identify the proper route; pause and ask the pharmacist or waste lead if classification or instructions are unclear. The outline does not establish a universal disposal route, and this guide does not invent one.
Apply it
A product or residue is identified as potentially hazardous or P-listed, but the container's designated waste instructions are unclear. Keep it from being handled as routine waste, follow the site's applicable procedure, and contact the designated responsible person.
Common pitfall: Do not assume every medicine belongs in the same waste container or choose sink, trash, or take-back disposal by guesswork. Do not infer a specific route from the outline alone.
Patient Safety and Quality Assurance23.75%
26.What makes insulin a high-alert medication?
High-alert medicines can cause significant harm when used in error; the designation does not mean every use is inappropriate. ISMP identifies insulin as high-alert in community and ambulatory care. Apply pharmacy safeguards and verify product, concentration, patient, and order through required workflow. The outline includes high-alert medications; ISMP supports this example and its safety meaning. Double-checks must follow authorized procedure.
Apply it
Two insulin products are stored near each other. Use required identification checks and do not select a product based only on a familiar brand name or package appearance.
Common pitfall: Do not treat a high-alert label as a substitute for checking the exact product and prescription. Confirm details through required workflow.
PTCE Content Outline, effective January 6, 2026 · ISMP: High-Alert Medications in Community/Ambulatory Care Settings
27.How can look-alike or sound-alike medicines be handled more safely?
LASA medicines may be confused because names or packages resemble one another. Safeguards include separating inventory when appropriate, reading the complete name, and using system and label checks. Tall Man lettering can help distinguish selected names but does not replace verification. The cited IHS resource is dated 2019 and is a general safety resource, not the examination outline. Use complete product details and current local safeguards.
Apply it
A pick list shows two similarly named products with different strengths. Compare the full name and strength against the order before selecting and scanning.
Common pitfall: Do not rely on package color, shelf position, or Tall Man lettering alone. Verify complete product details.
PTCE Content Outline, effective January 6, 2026 · Indian Health Service: Look Alike, Sound Alike Medications
28.Which details qualify as reliable patient identifiers?
Use person-specific identifiers, such as name and date of birth, according to workflow. A room number or location is not reliable because it can change or be shared. Match the prescription and product to the individual using required identifiers before handoff. The cited Joint Commission source gives identifier examples and excludes room number; follow the applicable local identity-check process. Use the identifiers required by the setting.
Apply it
Two patients share a surname. Confirm required person-specific identifiers before attaching a prescription to either record or completing handoff. Follow the local procedure.
Common pitfall: Do not use a room, bed, or queue number as an identifier merely because it appears on a label. Follow local procedure.
PTCE Content Outline, effective January 6, 2026 · Joint Commission: Two Patient Identifiers
29.Why is a leading zero safer than a trailing zero?
A leading zero before a decimal makes a value below one easier to see; an unnecessary trailing zero may be missed and make a dose appear larger. Write 0.5 rather than .5, and avoid 5.0 when the zero adds no meaning. Follow authorized correction procedures when a record needs correction. Preserve the intended value while improving legibility. Use approved record procedures; verify meaning if uncertain. The Joint Commission FAQ supports this notation principle.
Apply it
A dose is documented as .5 mL. Correct it to 0.5 mL through the authorized record-correction process, preserving the intended dose as required. Verify meaning if uncertain.
Common pitfall: Do not remove a leading zero or add an unnecessary trailing zero while reformatting an order. Preserve the value and follow correction procedure.
PTCE Content Outline, effective January 6, 2026 · Joint Commission: Abbreviations, Symbols and Dose Designations
30.How does barcode scanning reduce medication errors?
Barcode scanning can compare a product or patient identifier with system information and help detect a mismatch. It is a safeguard, not a guarantee: scanning the wrong item or bypassing an alert can defeat its purpose. Follow workflow and investigate a mismatch rather than treating it as noise. The outline lists barcode use as an error-prevention strategy. Technology supports deliberate verification; it does not replace it.
Apply it
A scan alert says the selected package does not match the prescription. Stop, compare complete product details, and ask the pharmacist to resolve uncertainty.
Common pitfall: Do not override a mismatch merely to complete a transaction quickly. Investigate the alert through required workflow.
31.When must a technician escalate an issue to the pharmacist?
The outline identifies pharmacist-intervention issues such as DUR concerns, adverse events, OTC recommendations, therapeutic substitution, misuse, adherence, allergies, and interactions. Recognize the signal, gather accurate information, and transfer the question promptly. The pharmacist makes clinical assessments and decisions, including whether a medicine should be started, stopped, substituted, or changed. This boundary applies even when a patient has used a medicine before.
Apply it
A patient asks whether an OTC product is safe with a prescription. Do not recommend a product; connect the patient with the pharmacist for review. Ask and relay relevant details according to procedure.
Common pitfall: Do not resolve a clinical alert based only on a previous fill or unverified statement. Preserve information and escalate it.
32.What separates a near miss from an adverse event?
A near miss is an error or hazardous condition intercepted before reaching the patient. An adverse event involves harm associated with care, though not every adverse event necessarily results from an error. Report both as procedure requires; accurate reporting can reveal safety improvements. AHRQ distinguishes these categories and the outline includes near-miss and event reporting. Do not infer causation solely from the event label.
Apply it
A wrong strength is caught during final checking before pickup. Record it through the near-miss process even though the patient received no medication.
Common pitfall: Do not omit a near miss because no injury occurred or label every adverse event proof of an error. Use event definitions accurately.
PTCE Content Outline, effective January 6, 2026 · AHRQ PSNet: Adverse Events, Near Misses, and Errors
33.How does root-cause analysis improve medication safety?
Root-cause analysis examines underlying system factors rather than stopping at the last person's action. Contributors may include workflow design, confusing labels, staffing, or communication. The goal is corrective action that reduces recurrence, not automatic blame. AHRQ describes this system-focused approach; the outline includes RCA and continuous quality improvement. Review whether corrective action works, not merely whether it was announced.
Apply it
Repeated selection errors occur between adjacent products. Review layout, labeling, and verification steps, then test a targeted change and evaluate results.
Common pitfall: Do not conclude that retraining one individual alone addresses a recurring system condition. Assess the process and recurrence.
PTCE Content Outline, effective January 6, 2026 · AHRQ PSNet: Root Cause Analysis
34.When is MedWatch a relevant reporting route?
FDA MedWatch accepts voluntary reports involving adverse events, medication errors, and product-quality problems for medical products. Notify the pharmacist and follow organizational procedure; the pharmacist or responsible person determines whether external reporting is appropriate. MedWatch does not replace immediate response to an urgent event. The outline includes MedWatch as an event-reporting example. Report facts accurately without claiming causation.
Apply it
A patient reports a suspected medicine reaction. Record the report accurately, alert the pharmacist, and follow the pharmacy process for deciding whether an FDA report is appropriate.
Common pitfall: Do not promise that a report proves causation or delay urgent care while completing paperwork. Follow immediate-response procedure first.
PTCE Content Outline, effective January 6, 2026 · FDA: Medical Product Safety Information
35.Which details help classify a prescription error?
Prescription errors can involve the wrong patient, drug, dose, quantity, or route. Compare the prescription and processed order element by element to identify the category. Accurate classification supports correction and quality review. If an error may have reached a patient, notify the pharmacist promptly and follow the response process. The outline lists these categories; a correct drug name alone does not establish a correct prescription.
Apply it
The correct medicine and patient are selected, but the entered quantity differs from the prescription. Identify the quantity discrepancy and escalate before dispensing.
Common pitfall: Do not assume a correct drug name makes an order error-free. Verify patient, dose, quantity, and route as well.
PTCE Content Outline, effective January 6, 2026 · AHRQ PSNet: Adverse Events, Near Misses, and Errors
36.When is soap and water appropriate for hand hygiene?
CDC guidance calls for washing with soap and water when hands are visibly soiled. Use the condition of the hands and task-specific procedure to select the method. Hand hygiene does not replace equipment cleaning or required PPE. The visible-soil condition is the distinguishing cue. Follow facility procedure and training instructions for other hand-hygiene moments too; hand hygiene reduces contamination risk but does not clean work surfaces.
Apply it
After handling a visibly soiled item, wash with soap and water before returning to clean work, following facility procedure and training instructions.
Common pitfall: Do not rely on sanitizer alone when hands are visibly dirty. Hand hygiene also does not clean equipment or surfaces.
PTCE Content Outline, effective January 6, 2026 · CDC: Clinical Safety — Hand Hygiene for Healthcare Workers
37.How should counting trays and work surfaces be kept safe?
Counting trays, countertops, and equipment can transfer residue or contaminants between tasks if not cleaned as required. Follow the pharmacy cleaning schedule and product directions, including required contact time. The outline includes cleaning standards but does not prescribe one universal product or interval for every setting. Use dedicated tools or added precautions when required by policy. Do not improvise a cleaning method when a hazard is unclear.
Apply it
A tray was used for a product with a residue concern. Follow the designated cleaning process before using it for another task, and document cleaning if required.
Common pitfall: Do not assume a quick wipe is adequate when the cleaning product requires a specific method or contact time. Follow site procedure and product label.
PTCE Content Outline, effective January 6, 2026 · CDC: Clinical Safety — Hand Hygiene for Healthcare Workers
38.Why must protective equipment match the task?
PPE is selected according to exposure risk and workplace procedure. Gloves, gowns, or other barriers may be required for particular handling or cleaning tasks, but PPE does not replace hand hygiene, containment, or correct waste disposal. Follow training and hazard-specific instructions. The outline includes PPE but does not prescribe one equipment set for every task. Stop and seek guidance if the hazard or procedure is unclear.
Apply it
A task procedure requires gloves and a designated containment method. Confirm both are available and use them according to training before handling the material.
Common pitfall: Do not assume gloves alone make an unfamiliar or potentially hazardous task safe. Stop and seek guidance when uncertain.
39.How should an ambiguous or error-prone abbreviation be handled?
Abbreviations and symbols can be misread. If an order cannot be interpreted confidently, do not guess from context or enter a likely meaning. Preserve the original information and obtain pharmacist clarification through approved workflow. Patient safety takes precedence over speed. The outline includes abbreviation safeguards and terminology in order processing. Clarify before entry when ambiguity could change directions.
Apply it
A handwritten direction contains an unclear abbreviation that could change frequency. Hold entry and ask the pharmacist to obtain clarification through the approved process.
Common pitfall: Do not silently expand an ambiguous abbreviation based on what is common in your experience. A plausible guess can still change the order.
Order Entry and Processing22.50%
17.Which equipment and supplies may be needed for drug administration?
The outline names diabetic supplies, inhaler spacers, oral and injectable syringes, filters, dilution solutions, immunization supplies, and nebulizers. These serve different purposes. Match the requested supply to the route, product, and authorized directions; refer compatibility or technique uncertainty to the pharmacist. The outline supplies examples, not universal product-specific instructions. Selecting the correct supply is a processing task, not authority to change administration directions.
Apply it
An order requires a specified filter or dilution solution. Verify it against the order and product workflow rather than selecting a visually similar supply.
Common pitfall: Do not interchange administration supplies based on appearance or a broad category such as syringe. Confirm purpose and compatibility.
40.How do you calculate a liquid volume from a prescribed dose?
Use the labeled concentration and unit cancellation. For 250 mg per 5 mL and a stated 375 mg dose: 375 mg x 5 mL / 250 mg = 7.5 mL. Milligrams cancel, leaving milliliters. Confirm dose and concentration; this exercise is not authority to change an order. If real order details conflict or are missing, clarify with the pharmacist. Reverse-check by multiplying the volume by concentration and verify the units before accepting the result.
Apply it
For an exercise specifying 375 mg and 250 mg/5 mL, calculate 7.5 mL and reverse-check by multiplying the volume by the concentration. This is arithmetic practice, not a treatment recommendation.
Common pitfall: Do not invert the concentration ratio. Check that 7.5 mL at the stated concentration gives 375 mg and that units cancel to mL.
41.How can days supply be calculated from quantity and directions?
For clear, regular directions, divide quantity by the amount used each day. For 120 tablets at one tablet three times daily, daily use is three tablets and 120/3 = 40 days. Variable, PRN, tapering, or unclear directions may need clarification rather than simple division. Match the calculation to actual directions; do not invent missing use instructions. Tablets divided by tablets per day gives days. Use the pharmacist for unresolved ambiguities.
Apply it
An exercise gives 120 tablets and one tablet three times daily. Divide 120 by 3 tablets per day to obtain 40 days; confirm tablet units cancel to days.
Common pitfall: Do not divide by the number of doses without accounting for units per dose. Do not assume a fixed daily amount for variable directions.
42.How do you calculate stock volume for a dilution exercise?
Keep the stated concentration and target amount in consistent units. A 10% w/v stock contains 10 g per 100 mL, or 0.1 g/mL. To obtain 3 g: 3 g / 0.1 g/mL = 30 mL of stock. This is arithmetic practice, not compounding authorization. Real preparation requires authorized procedures and pharmacist direction. Convert the percentage to its base units first; check that grams cancel and the answer is volume. Do not perform a real preparation based on this exercise.
Apply it
For an exercise asking for 3 g from 10% w/v stock, calculate 30 mL and verify that units cancel. Do not treat the exercise as preparation authorization.
Common pitfall: Do not interpret 10% w/v as 10 g/mL. Convert to 0.1 g/mL before calculating, and do not treat arithmetic practice as preparation authorization.
43.Which metric conversions are useful for medication calculations?
Metric prefixes indicate powers of ten: 1 g = 1,000 mg, and 1 mg = 1,000 micrograms. Convert by identifying starting and target units, then check the direction of the numerical change. For example, 5,000 mg = 5 g. Keep units attached throughout. NIST provides the SI-prefix basis; the outline includes conversions. Check for a misplaced factor of 1,000 and use unit cancellation rather than decimal movement alone before accepting an answer.
Apply it
Convert 5,000 mg to grams by dividing by 1,000 mg/g, giving 5 g. Confirm the units cancel and the quantity is equivalent to the original amount. Check direction.
Common pitfall: Do not move a decimal from memory without identifying the units. A mistaken direction can produce a thousandfold error.
PTCE Content Outline, effective January 6, 2026 · NIST Guide to the SI: Chapter 4
44.How do frequency abbreviations affect a quantity calculation?
Frequency terms determine administrations per day and affect quantity and days supply. For example, b.i.d. means twice daily and t.i.d. means three times daily. Read the complete directions and determine units per administration. If an abbreviation or context is unclear, obtain pharmacist clarification rather than assuming its meaning. The outline includes Sig codes and calculations. Be precise about doses per day versus units per dose.
Apply it
An exercise says one capsule t.i.d. for 10 days. Three capsules daily for 10 days gives 30 capsules; verify the actual directions before entry if this is a real order.
Common pitfall: Do not confuse doses per day with units per dose. Both affect quantity; unclear directions must not be guessed.
45.Which device is appropriate for measuring a small oral-liquid volume?
A calibrated oral syringe is generally appropriate for a small oral-liquid volume because it has marked graduations. Match the units and capacity to the directions, and ensure it is an oral device rather than an injectable syringe. FDA guidance supports calibrated devices and matching units to directions. Refer uncertainty about the required volume or device to the pharmacist. Use the exact product directions and workflow.
Apply it
For directions calling for 2.5 mL, provide a suitable calibrated oral syringe with readable mL markings if appropriate to workflow, rather than an uncalibrated household spoon.
Common pitfall: Do not supply a device whose units do not match directions or confuse an oral syringe with an injection device.
PTCE Content Outline, effective January 6, 2026 · FDA: Dosage Delivery Devices for Orally Ingested OTC Liquid Drug Products
46.How should an administration device be matched to a dosage form?
Supplies depend on route and dosage form. An inhaler spacer, nebulizer, oral syringe, and injectable syringe serve different purposes and are not interchangeable. Check the prescription and product instructions; provide the specified supply through authorized workflow. Refer patient suitability or technique questions to the pharmacist. The PTCE outline explicitly includes administration equipment and supplies. Verify compatibility using exact product information when needed.
Apply it
A prescription is for an inhaled medicine and a spacer is requested. Confirm compatibility with the selected inhaler and refer technique questions to the pharmacist.
Common pitfall: Do not select equipment based on appearance or because it measures a liquid. Match the device to route and product instructions.
47.What information does an NDC identify?
NDC data identify labeler, product, and package information. The identifier can distinguish products that share a drug name but differ in strength, form, or package. Compare NDC and package details when verifying stock. FDA's announced uniform 12-digit format is effective March 7, 2033; it is not already effective in October 2026. Check current product identification rather than assuming the future format is in force.
Apply it
Two packages have the same ingredient but different strengths. Compare product identifiers and package details before selecting the item that matches the prescription.
Common pitfall: Do not assume all current NDCs already use the announced future format. Check the actual product and current identification process.
PTCE Content Outline, effective January 6, 2026 · FDA: Drug NDC Data Reference · FDA: National Drug Code Format
48.Why should lot number and expiration date be checked together?
A lot number traces a production batch, while an expiration date indicates the labeled use period. Both matter for recalls, product-quality investigations, and stock rotation. Match a recall notice to the exact lot and remove expired products from dispensable stock according to procedure. FDA advises against using expired medicines; the outline includes these identifiers. Use the complete notice and actual package details.
Apply it
A recall notice names a product and lot. Compare both details with stock, isolate matching packages, and document the action through recall workflow. Check packages individually.
Common pitfall: Do not assume every package is affected by a lot-specific recall. Do not overlook an affected package because it looks normal.
PTCE Content Outline, effective January 6, 2026 · FDA: Don't Be Tempted to Use Expired Medicines
49.When should a product be removed from dispensable stock?
Expired, damaged, recalled, or otherwise non-dispensable products should not remain available for routine dispensing. Identify the reason, segregate as required, and follow the site's authorized return, disposal, or reverse-distribution process. Physical appearance alone does not establish usability. The outline distinguishes dispensable, non-dispensable, and expired stock; procedure determines authorized disposition. Do not put unsuitable items back into active inventory.
Apply it
A package is found beyond its expiration date. Remove it from active stock and follow the documented disposition process for that product. Record action if required.
Common pitfall: Do not return an expired medicine to the shelf because its package appears undamaged or a patient requests it.
PTCE Content Outline, effective January 6, 2026 · FDA: Don't Be Tempted to Use Expired Medicines
50.How does return-to-stock differ from reverse distribution?
Return-to-stock generally concerns an eligible, unclaimed prescription returned to pharmacy inventory after required checks. Reverse distribution is a separate channel for handling certain non-dispensable products. Neither process means every returned item can be reused. Verify integrity, storage history, legal restrictions, and eligibility under procedure. The outline lists return to stock, credit return, and reverse distribution as distinct concepts. Patient-returned or compromised medication should not be treated as ordinary stock.
Apply it
A prepared prescription is not picked up and remains within required conditions. Use return-to-stock only after confirming eligibility under pharmacy procedure.
Common pitfall: Do not return patient-returned or compromised medication to saleable inventory merely because its label remains intact. Check eligibility and integrity first.
51.Which supplies match an insulin delivery system?
An insulin pen, a vial used with an insulin syringe, pen needles, and glucose-monitoring supplies serve different functions. Match supplies to the prescribed insulin product and delivery device, using exact product information and authorized workflow. The outline names diabetic supplies; ISMP identifies insulin as high-alert. Refer uncertain compatibility or technique questions to the pharmacist. Do not substitute supplies by category alone.
Apply it
An order specifies insulin in a pen, but an insulin syringe is selected. Pause and verify compatible supplies through authorized workflow before dispensing.
Common pitfall: Do not assume a syringe, pen needle, or glucose-testing supply replaces another just because all relate to diabetes care.
PTCE Content Outline, effective January 6, 2026 · ISMP: High-Alert Medications in Community/Ambulatory Care Settings
52.How should an unclear dose or concentration calculation be resolved?
A calculation is only as reliable as its units and instructions. Write known dose, concentration, and requested output with units; arrange the ratio so unwanted units cancel, then reverse-check. If a needed value is missing or the result conflicts with the product, do not invent assumptions. Escalate the ambiguity to the pharmacist. Arithmetic cannot repair incomplete order information. Use the actual prescription and exact product.
Apply it
A problem supplies concentration but no prescribed dose. Identify the missing information and request clarification rather than calculating a volume from incomplete data.
Common pitfall: Do not fill in a missing dose from a typical regimen or another patient's prescription. Clarify missing or ambiguous information.
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- Give Medications the largest study share: practice name and class recognition, dosage forms and routes, interaction cues, and product-specific storage or stability.
- Study Federal Requirements across hazardous and non-hazardous waste recognition, controlled-substance schedules and prescription workflows, restricted programs including REMS, recalls, and DSCSA quarantine. The waste outline identifies the topic but does not establish a single disposal route; use applicable requirements and procedures rather than guessing.
- For Patient Safety and Quality Assurance, practice correct-patient checks, LASA and high-alert safeguards, pharmacist escalation, reporting, and system-focused improvement.
- For Order Entry and Processing, use unit-labeled calculations and reverse checks; include administration supplies, NDC/lot/expiry checks, and stock disposition.
- Use the outline effective January 6, 2026. Do not treat removed nonsterile compounding and alligation as standalone topics.
- Treat these independent questions as topic practice, not an exam simulation, timing claim, or pass prediction.
A practical preparation plan
1. Anchor study to the correct examination
CPhT is the PTCB credential and PTCE is its associated examination. Read the January 2026 effective outline and note the four domain weights.
2. Practice federal workflows with boundaries
For controlled substances, identify schedule and transaction type before proceeding; do not assume a transfer permits a prohibited refill. For REMS, recognize the flag, follow the program's current workflow, and escalate uncertainty. For pharmaceutical waste, identify the issue and use applicable current requirements and workplace procedures; do not invent a universal disposal route.
3. Use product information for drug facts
For administration, stability, storage, or adverse-effect examples, consult the exact product labeling. The outline defines examination scope; it is not individualized clinical guidance.
4. Practice calculations with units
Write units into each ratio, cancel units before calculating, and reverse-check. If a prompt omits a needed value or direction, identify the gap instead of inventing information.
5. Rehearse the technician-pharmacist boundary
Recognize interaction, allergy, adverse-effect, misuse, substitution, adherence, and OTC questions as escalation cues. Preserve accurate information and hand it off promptly.
6. Check legal scope and format facts
Study the cited federal baseline but check state requirements for practice. The PTCE has 90 multiple-choice items, 80 scored and 10 unscored. It is computer-based and administered in person at Pearson centers; a two-hour appointment includes the 110-minute exam.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- PTCB: Become a Certified Pharmacy Technician (CPhT)
- PTCE Content Outline, effective January 6, 2026
- PTCB: PTCE Job Analysis Study
- PTCB: At-a-Glance: CPhT Exam
- DailyMed: LIPITOR — atorvastatin calcium
- DailyMed: Warfarin sodium tablets
- DailyMed: NITROSTAT — nitroglycerin tablets
- DailyMed: Metformin hydrochloride extended-release tablets
- DailyMed: Levothyroxine sodium tablets
- DailyMed: Albuterol sulfate HFA inhalation aerosol
- DailyMed: Amoxicillin for oral suspension
- 21 CFR 1306.12: Refilling prescriptions; issuance of multiple prescriptions
- 21 CFR 1306.22: Refilling of prescriptions
- DEA Diversion Control Division: CMEA General Information
- FDA: Understanding Drug Recalls
- FDA: Pharmacists — Utilize DSCSA Requirements to Protect Your Patients
- FDA: Notify FDA of Illegitimate Products
- ISMP: High-Alert Medications in Community/Ambulatory Care Settings
- Joint Commission: Abbreviations, Symbols and Dose Designations
- Joint Commission: Two Patient Identifiers
- CDC: Clinical Safety — Hand Hygiene for Healthcare Workers
- AHRQ PSNet: Adverse Events, Near Misses, and Errors
- AHRQ PSNet: Root Cause Analysis
- FDA: Medical Product Safety Information
- NIST Guide to the SI: Chapter 4
- FDA: Dosage Delivery Devices for Orally Ingested OTC Liquid Drug Products
- FDA: Drug NDC Data Reference
- FDA: National Drug Code Format
- FDA: Don't Be Tempted to Use Expired Medicines
- Indian Health Service: Look Alike, Sound Alike Medications
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.